CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight’s orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and TRX’s dCELL® decellularization platform.
CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight's orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies...
CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight’s orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and TRX’s dCELL® decellularization platform.
Copy to clipboard 
